Cumulative data highly support TAT-MTS(cs)-Frataxin as Protein Replacement Therapeutic Candidatefor Friedreich’s Ataxia
Tuesday, June 23, 2015
TAT-MTS-FXN Protein as Replacement Therapy for Friedreich’s Ataxia
TAT-MTS-FXN Protein as Replacement Therapy for Friedreich’s Ataxia, Dalia Megiddo, MD, Chief Development Officer, Hagar Greif, PhD, Senior Director of Pre Clinical Studies.
Cumulative data highly support TAT-MTS(cs)-Frataxin as Protein Replacement Therapeutic Candidatefor Friedreich’s Ataxia
Cumulative data highly support TAT-MTS(cs)-Frataxin as Protein Replacement Therapeutic Candidatefor Friedreich’s Ataxia
